<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Elanco Animal Health — News on 6ix</title>
<link>https://6ix.com/company/elanco-animal-health</link>
<description>Latest news and press releases for Elanco Animal Health on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 22:23:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/elanco-animal-health" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683562a978dffbe2df0eeed7.webp</url>
<title>Elanco Animal Health</title>
<link>https://6ix.com/company/elanco-animal-health</link>
</image>
<item>
<title>Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock</title>
<link>https://6ix.com/company/elanco-animal-health/news/elancos-negasunttm-powder-coumaphos-propoxur-sulfanilamide-topical-powder-and-tanidiltm-coumaphos-propoxur-receive-emergency-authorization-for-use-against-new-world-screwworm-in-livestock</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elancos-negasunttm-powder-coumaphos-propoxur-sulfanilamide-topical-powder-and-tanidiltm-coumaphos-propoxur-receive-emergency-authorization-for-use-against-new-world-screwworm-in-livestock</guid>
<pubDate>Mon, 27 Apr 2026 22:23:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Negasunt Powder (coumaphos, propoxur, sulfanilamide topical powder) and a Section 18 Emergency Exemption from the U.S. Environmental Protection Agency (EPA) in cooperation with the United States Department of Agriculture (USDA) for Tanidil (coumaphos, propoxur) for the prevention and treatment of New World screwworm infestations in a vari</description>
</item>
<item>
<title>Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-confirms-date-and-conference-call-for-first-quarter-2026-financial-results-announcement</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-confirms-date-and-conference-call-for-first-quarter-2026-financial-results-announcement</guid>
<pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.</description>
</item>
<item>
<title>Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes*</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-launches-advantagetm-collar-for-dogs-with-four-months-of-continuous-protection-from-fleas-ticks-and-mosquitoes</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-launches-advantagetm-collar-for-dogs-with-four-months-of-continuous-protection-from-fleas-ticks-and-mosquitoes</guid>
<pubDate>Thu, 09 Apr 2026 12:27:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) today announced the launch of its Advantage™ Collar for Dogs, a new product providing long-lasting protection against two parasites that don't take a season off – fleas and ticks. Designed for dogs and puppies 12 weeks of age and older, this dog collar kills and repels fleas and ticks and repels mosquitoes* for a full four months.</description>
</item>
<item>
<title>Amlan International and Elanco Collaborate on Japanese Educational Seminars Focused on Calf Health</title>
<link>https://6ix.com/company/elanco-animal-health/news/amlan-international-and-elanco-collaborate-on-japanese-educational-seminars-focused-on-calf-health</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/amlan-international-and-elanco-collaborate-on-japanese-educational-seminars-focused-on-calf-health</guid>
<pubDate>Thu, 26 Feb 2026 21:00:00 GMT</pubDate>
<description>Amlan International and Elanco Collaborate on Japanese Educational Seminars Focused on Calf Health Amlan® International will collaborate with Elanco Animal Health on a three-day educational seminar in Japan from March 10–12 titled: “Creating the Future for Calves: Latest Clinical Approaches for Suckling Calves.” CHICAGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Amlan® International, the animal health business of Oil-Dri® Corporation of America (NYSE: ODC), will collaborate with Elanco Animal Health on</description>
</item>
<item>
<title>Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-animal-health-reports-fourth-quarter-and-full-year-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-animal-health-reports-fourth-quarter-and-full-year-2025-results</guid>
<pubDate>Tue, 24 Feb 2026 11:27:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2025 and provided initial guidance for both the first quarter and full year 2026.</description>
</item>
<item>
<title>Elanco to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Thu, 19 Feb 2026 13:00:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.</description>
</item>
<item>
<title>Elanco Announces Updates to Board of Directors</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-announces-updates-board-directors-142400658</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-announces-updates-board-directors-142400658</guid>
<pubDate>Fri, 13 Feb 2026 14:24:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to its Board of Directors. R. David Hoover and Deborah Kochevar will not stand for re-election at the conclusion of their terms at the 2026 Annual Meeting of Shareholders in May.</description>
</item>
<item>
<title>Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-confirms-date-and-conference-call-for-fourth-quarter-and-full-year-2025-financial-results-announcement</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-confirms-date-and-conference-call-for-fourth-quarter-and-full-year-2025-financial-results-announcement</guid>
<pubDate>Thu, 22 Jan 2026 13:00:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.</description>
</item>
<item>
<title>Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Tue, 06 Jan 2026 13:00:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).</description>
</item>
<item>
<title>Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-receives-usda-approval-for-befrenatm-tirnovetmab-a-new-anti-il31-monoclonal-antibody-injection-targeting-canine-allergic-and-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-receives-usda-approval-for-befrenatm-tirnovetmab-a-new-anti-il31-monoclonal-antibody-injection-targeting-canine-allergic-and-atopic-dermatitis</guid>
<pubDate>Wed, 31 Dec 2025 19:00:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) today announced its latest entry into the rapidly growing canine dermatology space with the U.S. Department of Agriculture (USDA) approval of Befrena™ (tirnovetmab), a new anti-IL31 monoclonal antibody (mAb) injection targeting canine allergic and atopic dermatitis. Importantly, Befrena is recommended at a dosing interval of 6 to 8 weeks post-treatment, which stands in contrast to the 4 to 8 weeks of the current market competitor, lokivetmab.</description>
</item>
<item>
<title>Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs</title>
<link>https://6ix.com/company/elanco-animal-health/news/elancos-credelio-quattrotm-ca1-lotilaner-moxidectin-praziquantel-and-pyrantel-chewable-tablets-receives-first-fda-conditional-approval-for-treatment-of-new-world-screwworm-in-dogs</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elancos-credelio-quattrotm-ca1-lotilaner-moxidectin-praziquantel-and-pyrantel-chewable-tablets-receives-first-fda-conditional-approval-for-treatment-of-new-world-screwworm-in-dogs</guid>
<pubDate>Thu, 18 Dec 2025 13:43:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) for Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) for the treatment of infestations caused by New World screwworm larvae (myiasis) in dogs. This is the first FDA conditional approval for a companion animal product to treat New World screwworm.</description>
</item>
<item>
<title>Elanco Announces Investment in U.S. Manufacturing and R&D, Driven by Tax, Tariff and Regulatory Clarity</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-announces-investment-in-us-manufacturing-and-randd-driven-by-tax-tariff-and-regulatory-clarity</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-announces-investment-in-us-manufacturing-and-randd-driven-by-tax-tariff-and-regulatory-clarity</guid>
<pubDate>Wed, 17 Dec 2025 14:30:00 GMT</pubDate>
<description>NORTHAMPTON, MA / ACCESS Newswire / December 17, 2025 / Elanco announced $400 million in continued investment in its U.S. operations, workforce and communities over the next five years. This deepens Elanco's commitment to product innovation, advanced ...</description>
</item>
<item>
<title>Elanco Investor Day Defines New Era as Sustainable Growth Company</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-investor-day-defines-new-era-as-sustainable-growth-company</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-investor-day-defines-new-era-as-sustainable-growth-company</guid>
<pubDate>Tue, 09 Dec 2025 12:40:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) hosts its first Investor Day in five years this morning, marking a pivotal moment as the company further defines its new era of sustainable growth and long-term value creation. Elanco will detail how its consistent Innovation, Portfolio and Productivity (IPP) strategy is designed to guide the company's transformation to a sustainable growth company, delivering consistent mid-single digit organic constant currency revenue growth and adjusted EBITDA m</description>
</item>
<item>
<title>Elanco executive appointed as Neurizon's Board Observer</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-executive-appointed-as-neurizons-board-observer</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-executive-appointed-as-neurizons-board-observer</guid>
<pubDate>Wed, 26 Nov 2025 23:15:00 GMT</pubDate>
<description>Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</description>
</item>
<item>
<title>Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats</title>
<link>https://6ix.com/company/elanco-animal-health/news/elancos-credeliotm-cat-lotilaner-receives-first-fda-emergency-use-authorization-eua-for-treatment-of-new-world-screwworm-nws-in-cats</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elancos-credeliotm-cat-lotilaner-receives-first-fda-emergency-use-authorization-eua-for-treatment-of-new-world-screwworm-nws-in-cats</guid>
<pubDate>Fri, 21 Nov 2025 18:35:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Credelio™ CAT (lotilaner) to treat New World screwworm (NWS) infestations in cats. This authorization represents the first EUA granted by the FDA for New World screwworm treatment in felines.</description>
</item>
<item>
<title>Elanco to Participate in the Upcoming Investor Conferences</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-to-participate-in-the-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-to-participate-in-the-upcoming-investor-conferences</guid>
<pubDate>Thu, 20 Nov 2025 13:00:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.</description>
</item>
<item>
<title>Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health</title>
<link>https://6ix.com/company/elanco-animal-health/news/alloy-partners-launches-onehealth-studio-to-create-startups-at-the-convergence-of-animal-plant-and-human-health</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/alloy-partners-launches-onehealth-studio-to-create-startups-at-the-convergence-of-animal-plant-and-human-health</guid>
<pubDate>Thu, 13 Nov 2025 13:00:00 GMT</pubDate>
<description>Alloy Partners today announced the launch of OneHealth Studio, a first-of-its-kind venture studio designed specifically to create and scale new companies at the convergence of animal, plant and human health in partnership with Elanco Animal Health (NYSE: ELAN).</description>
</item>
<item>
<title>Elanco Animal Health Reports Third Quarter 2025 Results</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-animal-health-reports-third-quarter-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-animal-health-reports-third-quarter-2025-results</guid>
<pubDate>Wed, 05 Nov 2025 11:27:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2025, provided guidance for the fourth quarter of 2025, and updated guidance for the full year 2025.</description>
</item>
<item>
<title>Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species</title>
<link>https://6ix.com/company/elanco-animal-health/news/elanco-announces-expansion-of-credelio-quattrotm-lotilaner-moxidectin-praziquantel-and-pyrantel-chewable-tablets-and-credeliotm-lotilaner-labels-offering-protection-against-lyme-disease-and-an-emerging-tick-species</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elanco-announces-expansion-of-credelio-quattrotm-lotilaner-moxidectin-praziquantel-and-pyrantel-chewable-tablets-and-credeliotm-lotilaner-labels-offering-protection-against-lyme-disease-and-an-emerging-tick-species</guid>
<pubDate>Mon, 27 Oct 2025 10:27:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) today announced label expansions for two of its leading canine prescription parasiticides, Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio (lotilaner), with both product labels updated to include:</description>
</item>
<item>
<title>Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs</title>
<link>https://6ix.com/company/elanco-animal-health/news/elancos-credeliotm-lotilaner-receives-first-ever-fda-emergency-use-authorization-eua-against-new-world-screwworm-nws-in-dogs</link>
<guid isPermaLink="true">https://6ix.com/company/elanco-animal-health/news/elancos-credeliotm-lotilaner-receives-first-ever-fda-emergency-use-authorization-eua-against-new-world-screwworm-nws-in-dogs</guid>
<pubDate>Fri, 24 Oct 2025 20:55:00 GMT</pubDate>
<description>Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Credelio™ (lotilaner) to treat New World screwworm (NWS) infestations in dogs. This is the first EUA ever granted by the Agency for NWS in dogs. Confirmed cases of NWS have been detected less than 70 miles south of the U.S.-Mexico border.ii This Emergency Use Authorization allows veterinarians and pet owners to have a ready-now trea</description>
</item>
</channel>
</rss>